

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 40142

Manuscript Type: MINIREVIEWS

Biosimilars in paediatric inflammatory bowel disease

Sieczkowska-Golub J *et al.* Biosimilars in paediatric IBD

Joanna Sieczkowska-Golub, Dorota Jarzebicka, Grzegorz Oracz, Jaroslaw Kierkus

Abstract

The introduction of biological treatments has changed disease outcomes for patients with inflammatory bowel disease. Biologicals have high efficacy, and can induce and maintain remission after failed responses to conventional immunosuppressive and/or steroid therapy. The increasing occurrence of severe disease at diagnosis has resulted in infliximab being more often introduced as the first-line treatment in a 'top-down' approach. Besides their favourable efficacy and safety profile, biologicals have one significant disadvantage, which is their high cost. This results in many patients stopping therapy prematurely, with the maintenance phase being too short. This often leads to disease exacerbation shortly after treatment cessation. Every newly started

Match Overview

1	Internet 34 words crawled on 27-Mar-2016 www.espgan.org	1%
2	Crossref 26 words Ben Kang, Yoon Lee, Kiwuk Lee, Young Ok Choi, Yon Ho C hoe. "Long-term Outcomes After Switching to CT-P13 in Pe	1%
3	Internet 15 words crawled on 01-Jun-2018 www.thieme-connect.com	1%
4	Internet 13 words crawled on 01-Dec-2017 www.bmj.com	<1%
5	Crossref 12 words Massimo Radin, Savino Sciascia, Dario Roccatello, Maria J ose Cuadrado. "Infliximab Biosimilars in the Treatment of I...	<1%
6	Internet 12 words crawled on 12-Sep-2017 link.springer.com	<1%



时间不限

2018以来

2017以来

2014以来

自定义范围...

按相关性排序

按日期排序

不限语言

中文网页

简体中文网页

☒ 包括专利

☐ 包含引用

☒ 创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置. 指定搜索语言

Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations

[HTML] oup.com

J Sieczkowska, D Jarzębicka... - Journal of Crohn's ..., 2015 - academic.oup.com

Background and aims: The growing incidence of inflammatory bowel disease (IBD) in children necessitates the use of biological treatments. Recently, an infliximab biosimilar was authorized in the European Union, which may result in switching patients. We present our ...

☆ 被引用次数: 81 相关文章 所有 4 个版本

Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN Paediatric IBD Porto Group

[PDF] naspghan.org

L De Ridder, M Waterman, D Turner... - Journal of pediatric ..., 2015 - journals.lww.com

Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market. This will most likely lead to decreased drug costs and so easier access to these expensive agents. Extrapolation, however, of the limited available ...

☆ 被引用次数: 26 相关文章 所有 13 个版本

[HTML] Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort ...

[HTML] oup.com

LJT Smits, LAAP Derikx, DJ de Jong... - Journal of Crohn's ..., 2016 - academic.oup.com

... Article Navigation. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. Lisa JT Smits. a. Inflammatory Bowel Disease ...

☆ 被引用次数: 78 相关文章 所有 7 个版本

[HTML] Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort

[HTML] oup.com

KB Gecse, BD Lovász, K Farkas, J Banai... - Journal of Crohn's ..., 2015 - academic.oup.com

... Article Navigation. Editor's Choice. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. Krisztina B. Gecse. a. First Department of Internal ...

☆ 被引用次数: 104 相关文章 所有 7 个版本

... disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-

[PDF] bio-similari.it

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 203,000 条结果 (用时 0.41 秒)

Google 学术: Biosimilars in paediatric inflammatory bowel disease

... in paediatric patients with inflammatory bowel disease. ... - Sieczkowska - 被引用次数: 81

... of biosimilars in paediatric inflammatory bowel disease ... - De Ridder - 被引用次数: 26

... to the biosimilar CT-P13 in inflammatory bowel disease ... - Smits - 被引用次数: 78

The use of biosimilars in paediatric inflammatory bowel disease. - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/28692448> - 翻译此页

作者: MME Jongsma - 2017 - 相关文章

PURPOSE OF REVIEW: After expiry of the patent of originator anti-tumor necrosis factor drug infliximab (Remicade), CT-P13 was in 2013 the first infliximab biosimilar to be approved by the European Medicine Agency (EMA) for the same indications as the reference drug, including paediatric inflammatory bowel disease (IBD) ...

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/26154031> ▼ 翻译此页

作者: L de Ridder - 2015 - 被引用次数: 26 - 相关文章

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. ... Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market.

Biosimilar infliximab use in paediatric IBD | Archives of Disease in ...

<https://adc.bmj.com/content/early/2017/10/07/archdischild-2017-313404> - 翻译此页

作者: L Richmond - 2017 - 被引用次数: 2 - 相关文章

Background Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety ...

[PDF] Use of biosimilars in paediatric inflammatory bowel disease - ESPGH...

www.espghan.org/.../Use_of_Biosimilars_in_Paediatric_Inflammatory.9785... ▼ 翻译此页

作者: L de Ridder - 被引用次数: 26 - 相关文章

A POSITION STATEMENT OF THE ESPGHAN paediatric IBD Porto GROUP behalf of the

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 203,000 条结果 (用时 0.41 秒)

Google 学术: Biosimilars in paediatric inflammatory bowel disease

... in paediatric patients with inflammatory bowel disease. ... - Sieczkowska - 被引用次数: 81

... of biosimilars in paediatric inflammatory bowel disease ... - De Ridder - 被引用次数: 26

... to the biosimilar CT-P13 in inflammatory bowel disease ... - Smits - 被引用次数: 78

The use of biosimilars in paediatric inflammatory bowel disease. - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/28692448> - 翻译此页

作者: MME Jongsma - 2017 - 相关文章

PURPOSE OF REVIEW: After expiry of the patent of originator anti-tumor necrosis factor drug infliximab (Remicade), CT-P13 was in 2013 the first infliximab biosimilar to be approved by the European Medicine Agency (EMA) for the same indications as the reference drug, including paediatric inflammatory bowel disease (IBD) ...

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/26154031> ▼ 翻译此页

作者: L de Ridder - 2015 - 被引用次数: 26 - 相关文章

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. ... Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market.

Biosimilar infliximab use in paediatric IBD | Archives of Disease in ...

<https://adc.bmj.com/content/early/2017/10/07/archdischild-2017-313404> - 翻译此页

作者: L Richmond - 2017 - 被引用次数: 2 - 相关文章

Background Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety ...

[PDF] Use of biosimilars in paediatric inflammatory bowel disease - ESPGH...

www.espghan.org/.../Use_of_Biosimilars_in_Paediatric_Inflammatory.9785... ▼ 翻译此页

作者: L de Ridder - 被引用次数: 26 - 相关文章

A POSITION STATEMENT OF THE ESPGHAN paediatric IBD Porto GROUP behalf of the